Merus N.V. appointed Jason Haddock as non-executive director.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
43.91 USD | -2.47% | -1.37% | +59.67% |
May. 13 | Merus Says US FDA Grants Breakthrough Therapy Designation for Petosemtamab | MT |
May. 13 | Merus Carcinoma Treatment Awarded US FDA's Breakthrough Therapy Designation | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+59.67% | 2.58B | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- MRUS Stock
- News Merus N.V.
- Merus N.V. Appoints Jason Haddock as Non-Executive Director